-transparent.png){kind=logo}
Twenty patients with advanced or recurrent uterine sarcoma no longer amenable to control with surgery and/or radiotherapy were entered into study by Gynecologic Oncology Group institutions to receive piperazinedione 9 mg/m2 intravenously every 3 weeks. One patient was deemed to be ineligible for study. Among the 19 evaluable patients, only one response was observed, a partial response in a patient with leiomyosarcoma. Adverse effects consisted primarily of myelosuppression and were tolerable. Piperazinedione at the dose and schedule tested appears to have little activity against uterine sarcomas.
Related Publications
J T Thigpen, and
J A Blessing, and
H D Homesley, and
N Hacker, and
S L Curry
August 2000,
American journal of clinical oncology,
J T Thigpen, and
J A Blessing, and
H D Homesley, and
N Hacker, and
S L Curry
December 2002,
Gynecologic oncology,
J T Thigpen, and
J A Blessing, and
H D Homesley, and
N Hacker, and
S L Curry
February 1993,
American journal of clinical oncology,
J T Thigpen, and
J A Blessing, and
H D Homesley, and
N Hacker, and
S L Curry
February 1990,
American journal of clinical oncology,
J T Thigpen, and
J A Blessing, and
H D Homesley, and
N Hacker, and
S L Curry
June 2003,
Gynecologic oncology,
J T Thigpen, and
J A Blessing, and
H D Homesley, and
N Hacker, and
S L Curry
August 1996,
Gynecologic oncology,
J T Thigpen, and
J A Blessing, and
H D Homesley, and
N Hacker, and
S L Curry
August 2000,
Gynecologic oncology,
J T Thigpen, and
J A Blessing, and
H D Homesley, and
N Hacker, and
S L Curry
February 2002,
Gynecologic oncology,
J T Thigpen, and
J A Blessing, and
H D Homesley, and
N Hacker, and
S L Curry
February 1983,
Cancer treatment reports,
J T Thigpen, and
J A Blessing, and
H D Homesley, and
N Hacker, and
S L Curry
January 2010,
Gynecologic oncology,
